Research Analysts’ Recent Ratings Changes for AngioDynamics (ANGO)

A number of research firms have changed their ratings and price targets for AngioDynamics (NASDAQ: ANGO):

• 10/15/2026 – AngioDynamics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/13/2026 – AngioDynamics had its price target lowered by HC Wainwright from $19.00 to $18.00. They now have a “buy” rating on the stock.
• 10/10/2026 – AngioDynamics was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/9/2026 – AngioDynamics had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $20.00 price target on the stock.
• 10/5/2026 – AngioDynamics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/22/2026 – AngioDynamics was upgraded by Wall Street Zen from “hold” to “buy”.

Insiders Place Their Bets

In related news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 6.00% of the company’s stock.

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.